1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C5641938526097D30025897B0031676A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medicals-road-map-for-social-media-success-oncology-structure-activities?opendocument
18
19opendocument
2018.97.14.80
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Affairs Excellence

Medical’s Road Map for Social Media Success in Oncology: Structure and Activities

ID: 5755


Features:

10 Info Graphics

18 Data Graphics

160+ Metrics


Pages/Slides: 34


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical’s Road Map for Social Media Success in Oncology: Structure and Activities”

STUDY OVERVIEW

Oncology manufacturers recognize the significant impact social media can have on Medical Affairs’ engagement with key stakeholders like thought leaders, health care providers, patients and digital opinion leaders. However, it is important for Medical Affairs leaders to identify the right organizational structure and activities to engage their target audiences effectively.

Best Practices, LLC conducted benchmarking research to develop a roadmap for Medical Affairs’ social media success in Oncology. The study examines the optimal structure for Medical Affairs groups within Oncology companies to engage in social media initiatives and highlights key social media activities for effectively educating the market.

It delivers benchmarks around social media account quantity, separation of accounts, share of account ownership, medical affairs involvement, vendor utilization, social media platforms utilized, target audiences, social media goals, proactive vs. reactive interaction proportions, and proactive social media activities for medical.



KEY TOPICS

  • Social Media Structure
  • Social Media Management in Oncology
  • Social Media Activities

KEY METRICS

  • What is the geographic span of responsibility of benchmarked Oncology organizations?
  • Do Oncology organizations have a single social media account or multiple?
  • What is the range of multiple social media accounts?
  • Please indicate how the organization’s social media accounts are separated
  • To what degree is the Medical Affairs function involved in social media initiatives at Oncology organizations?
  • To what degree does Medical Affairs share social media accounts with other groups in the organization?
  • Do Oncology Medical Affairs groups partner with third party vendors to support or drive social media activities?
  • Please indicate the social media platforms which are utilized by Oncology Medical Affairs groups
  • Which groups are target audiences for Medical’s social media activities?
  • Which goals are priorities for Medical Affairs group’s social media efforts?
  • What percentage of Medical Affairs’ social media engagements are currently proactive vs. reactive?
  • Please specify the proactive activities Oncology Medical Affairs group perform through their social media accounts
  • Please indicate how effective each social media platform is for each of the listed proactive activities
  • Please rate the effectiveness of proactive social media activities in engaging each target audience

SAMPLE KEY FINDINGS

  • Social Media Accounts: The consensus is that multiple avenues of outreach are most effective: The social scorecard shows multiple accounts maintained by 84% of oncology segment and 68% of rest of the benchmark class.

METHODOLOGY

Best Practices, LLC engaged 48 Medical leaders from 36 biopharma companies in this benchmarking research. For oncology therapeutic area-specific insights, two specific segments were investigated in this study: Responses from 19 social media leaders at 14 Oncology organizations were analyzed against the rest of the total benchmark class.

Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Manufacturing; Consumer Products; Diagnostic; Communications; Medical; Biopharmaceutical; Health Care; Consulting


Companies Profiled:
AbbVie; Avidity Biosciences; AstraZeneca; Baxter Healthcare; Bayer; BIAL; Boehringer Ingelheim; Boston Scientific; Complete HealthVizion | An IPG Health Company; Dompé; DURECT Corporation; Eisai; Elevation Oncology; EMD Serono; Ethicon Endo-Surgery Inc.; Gossamer Bio; Grifols; Hoya Vision Care; Janssen; LEO Pharma; MedVal Scientific Information Services; Merck KGaA; Merck Sharp & Dohme; Merz Pharma; Merz Aesthetics; Myovant Sciences; Nobel Biocare; Novartis; Novartis Oncology; Novo Nordisk; PRECISIONscientia; Servier; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.